drugset
drugset / Trial / NCT06352541

Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.

NCT06352541 ↗

Phase 1 Completed 28 enrolled Laboratorios Sophia S.A de C.V.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase I study evaluating safety and tolerability through the incidence of unexpected adverse events and IOP measurement, as well as through the incidence of stinging after its administration, compared to placebo.

Timeline

Start
2024-02-08
Primary completion
2024-05-28
Completion
2024-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.1 % Topical
Subject Moxifloxacin Small molecule 0.5 % Topical

Indications

No indication recorded.